A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.

Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ...

"Zymeworks reports Phase I data for ZW191 ADC" was originally created and published by Clinical Trials Arena, a GlobalData ...

The data, first presented at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting, showed that the phase 3 ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...

After surviving three types of cancer and having to face the harsh realities of colorectal and endometrial cancer and basal ...

Ibuprofen is a household name—the go-to remedy for everything from headaches to period pain. But recent research suggests ...

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, ...

A common painkiller, ibuprofen, is showing surprising potential beyond easing aches. Research suggests it might help combat ...

Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), ...

Investing.com -- PMV Pharmaceuticals Inc (NASDAQ:PMVP) stock rose 2.2% on Friday after the company reported encouraging clinical trial results for its cancer drug rezatapopt, showing responses across ...

Step Pharma is financed to move its pipeline-in-a-product strategy forward on a broad front, after raising a €38 million (US$44.2 million) series C. That will see three ongoing trials testing the ...